Media Releases

Find out about our current activities

Click on the media releases below to find out more about our current activities.

07.05.2015 - InSphero Launches Enhanced Ultra-low Attachment Spheroid Plate for Scaffold-free 3D Cell Culture

InSphero Launches Enhanced Ultra-low Attachment Plate
for Scaffold-free 3D Cell Culture

Schlieren, Switzerland, May 7, 2015 – GravityTRAP™ ULA Plate design simplifies medium exchange and improves imaging during spheroid production and culture.  PDF Version

InSphero AG, the leading provider of scaffold-free 3D microtissues, cell culture technology, and 3D-focused contract research testing, announced today the release of their new GravityTRAP™ Ultra-low Attachment (ULA) Plate. The automation-compatible 96-well ULA format expands InSphero's portfolio of tissue culture platforms for scaffold-free 3D cell culture, offering a low-cost, enhanced ULA plate ideal for production of 3D tumor microtissues derived from tumor cell lines, or to screen for the propensity of cells to form spheroids in a low-attachment environment.

The GravityTRAP™ ULA Plate includes wells specially coated to prevent attachment and monolayer growth of cells, and provides significant advantages over existing ultra-low attachment spheroid plates, including simplified medium exchange and improved imaging. Each well incorporates a SureExchange™ tapered ledge design that simplifies the process of changing growth medium during long term culture or compound dosing, and protects spheroids from disruption or accidental aspiration. The narrow (1 mm diameter) growth chamber in each well features a flat bottom, eliminating focal distortion that can
complicate imaging in round-bottom ULA plates.  The narrow chamber provides the necessary concentration of cells required to promote formation of a single microtissue per well, while making it easier to locate and image even small (<100 μm diameter) spheroids.

Users of InSphero's GravityPLUS™ hanging drop system will likely be familiar with the GravityTRAP™ ULA Plate, as it already serves as the long-term culture and assay plate provided with the patented hanging drop system. Dr. Simon Messner, Product Manager at InSphero, notes offering the GravityTRAP™ ULA Plate as a stand-alone platform offers a cost-effective option for researchers looking to move their cell culture into 3D, or who may currently be experiencing the limitations of existing ultra-low attachment plates. "We recommend the GravityTRAP™ ULA Plate as a first-line option for testing or confirming the spheroid-forming capacity of cells, particularly tumor cell lines, as they may not require the improved oxygenation and complete elimination of cell-surface interaction afforded by the hanging drop technique to form spheroids. The GravityPLUS™ system is still the platform of choice for production of more  complex 3D microtissues, such as those derived from patient- or animal-derived (primary) cells or multi-cell type co-culture models."

InSphero CEO and co-founder Dr. Jan Lichtenberg states the benefits of the new platform extend beyond its design features. "With the GravityTRAP™ ULA Plate and GravityPLUS™ system, researchers have not only two reliable scaffold-free platforms, but also the confidence of purchasing their technology from a company with extensive 3D cell culture experience and know-how. This includes specially formulated growth medium to promote spheroid formation or long-term culture maintenance, 3D-optimized protocols to help extract the most data, and custom model development and compound screening through our 3D InSight™ Services."

To find out more about the benefits of scaffold-free 3D cell culture, or to learn more about InSphero visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is the world's leading supplier of organotypic, biologically relevant in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top 15 global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup and ACES Award Winner for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

17.03.2015 - InSphero Publication Honored for Potential to Reduce Use of Research Animals

InSphero Publication Honored for Potential to Reduce Use of Research Animals

Schlieren, Switzerland, March 17, 2015 – Nature Communications paper co-authored with ETH Zurich wins "highly commended" honor from NC3Rs.  PDF Version

Research conducted by InSphero AG, the world’s leading supplier of 3D microtissues for in vitro safety and efficacy testing, and collaborators at ETH Zurich has received the “highly commended” honor from the British National Center for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs). Dr. Olivier Frey of ETH Zurich, first author on the paper published last June in the journal Nature Communications, accepted the award at the 3Rs Prize ceremony held last week in London.

The paper, entitled “Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis,” reported a novel approach to culturing multi-cellular 3D microtissues in vitro, and for the first time joined hanging drop cell culture with microfluidics. Growing spheroids in hanging drops removes restrictions associated with scaffolds, while microfluidics allow continuous medium and waste exchange, and allowing test substances such as candidate drugs to be dosed into the culture medium. The body-on-a-chip (BoC) system successfully displayed the ability to interconnect spheroids from two different tissue types (liver and tumor) which were able to communicate with each other via metabolite transfer. The principle was demonstrated using bioactivation of the anti-cancer drug Cyclophosphamide by the liver, and subsequent inhibition of tumor spheroid growth.

Dr. Jan Lichtenberg, CEO and co-founder of InSphero commented,”Multi-tissue in vitro test systems hold promise in the drug development industry as a better means of predicting the safety and efficacy of novel agents, while reducing the dependency on using animals for such studies.” Lichtenberg noted most BoC concepts to date focus on joining individual chambers of cells cultured in 2-dimensional monolayers, which is the current industry standard for most in vitro cell based assays. “Our 3D InSight™ Liver, Islet, and Tumor Microtissues continue to provide striking evidence that 3D cell culture displays a more organotypic, biologically relevant phenotype than 2D. Naturally it follows that interconnecting spheroids would be an ideal approach to recapitulating a multi-organ system, something this research conceives in a scalable and flexible BoC format.”

The collaboration has yielded two additional publications since the award winning Nature Communications paper last June, including recent articles in the Journal of Laboratory Automation and the Journal of Biotechnology.

NC3Rs is a UK-based scientific organization dedicated to replacing, refining and reducing the use of animals in research and testing. The 3Rs Prize is sponsored by GlaxoSmithKline.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

10.03.2015 - Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Proteomic Profiling of 3D Liver Microtissues Provides New Insight Into Acetaminophen Toxicity

Schlieren-Zurich, Switzerland, March 10, 2015 – InSphero, Biognosys paper reveals relevant proteomic changes in liver at sub-toxic doses.  PDF Version

InSphero AG, a leading supplier of 3D microtissues for in vitro safety and efficacy testing, and Biognosys AG, a leader in next-generation proteomics have teamed up to publish research in Molecular & Cellular Proteomics entitled "Extending the limits of quantitative proteome profiling with data-independent acquisition and application to acetaminophen treated 3D liver microtissues". The paper represents the latest milestone in characterizing InSphero's 3D microtissues as a superior model system for in vitro toxicity testing. The study was co-authored by researchers from Purdue University and ETH Zurich, and will be presented at the upcoming Society of Toxicology meeting in San Diego, California.

In the study, proteomic changes in acetaminophen (APAP)-treated 3D InSight™ Human Liver Microtissues were quantified with HRM-MS™, a next-generation proteomics technology developed by Biognosys that is based on data-independent acquisition (DIA) performed on new generation mass spectrometric systems. The abundance of 2,830 proteins was quantified over an APAP physiological concentration range with a starting material of 12,000 cells per sample. Proteins from all three phases of drug metabolism were identified as regulated. Moreover, for the first time the exact NAPQI‐cysteine adduct sites were mapped on proteins possibly relevant for the toxicity of APAP.

Dr. Jens M. Kelm, CSO and co-founder of InSphero stated "the combination of our organotypic 3D microtissue model system and the HRM profiling technology proved to be a powerful approach for discovery experiments, revealing novel modes‐of‐action, toxicity upon drug treatment, and new biomarkers. HRM-MS makes yet another useful endpoint available to our customers for extracting high-value information from our microtissues, particularly global proteomic changes in response to drug treatment."

Dr. Kelm noted the enhanced longevity and more native metabolic phenotype of 3D microtissues made them suitable for such long-term, repeat-dose toxicity studies, and importantly, the HRM approach was able to identify and quantify for the first time human protein targets of drug-adducts in sub-toxic APAP concentrations. InSphero's 3D InSight™ Human Liver Microtissues are established using primary human hepatocytes (PHH) and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing
Phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jens M Kelm, CSO and Co-Founder
Phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

About Biognosys

Biognosys is the leading proteomics company offering services and products for highly multiplexed protein quantification. Founded in 2008 as a spin-off
from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys is dedicated to transform life science with superior technology and software.

Contact: This email address is being protected from spambots. You need JavaScript enabled to view it., www.biognosys.ch

21.01.2015 - 3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

3D Liver Spheroid Model in Use by MIP-DILI, IMI's Drug Liver Injury Project

Schlieren, Switzerland, January 21, 2015 – European consortium will use 3D liver tissues to better predict drug-induced liver injury.  PDF Version

Leaders of the European project "Mechanism based Integrated systems for the Prediction of Drug Induced Liver Injury" (MIP-DILI) project have reported they will use 3-dimensional (3D) liver spheroids against a panel of other in vitro test systems aimed at developing novel preclinical tests to improve the safety evaluation of drugs likely to cause drug-induced liver toxicity before subsequent evaluation in clinical trials.  Along with its academic and EFPIA partners, the MIP-DILI consortium is funded equally by the EU Innovative Medicines Initiative (IMI) and EFPIA companies, and is in year three of the €32.4 million 5-year program.

In early project work, primary human hepatocytes (PHH), cells isolated from human liver donors, outperformed tumor-derived or other immortalized liver cell lines in terms of metabolic activity but with apparently mixed sensitivity to known DILI-inducing drugs.  InSphero, the leading supplier of 3D cell culture products and services to the  pharmaceutical industry, along with a number of other commercial technology suppliers were invited to participate in the next round of studies, where PHH were grown and assayed in a variety of formats that included static 2D culture, perfusion cultures, and 3D spheroids. Among the participating commercial suppliers contributing to the study, 3D spheroids emerged as the culture platform that most resembled liver-like biology and responded to a number of liver toxins with a certain enhanced sensitivity, which now requires further investigation.

Dr. Phil Hewitt, co-leader of the project's 'Established and novel in vitro cell systems' work package, says "3D spheroids proved to offer more than just superior biological relevance, they also provide the scalability and compatibility necessary to work with commercial assays and automation systems, and can do it at a more reasonable cost than other systems evaluated in the early phase studies.  Liver spheroids will play a key role in the predictive in vitro tests being developed as the project progresses."

The findings were presented last fall at EUROTOX 2014 in Edinburgh, UK, in talks that summarized a thorough two-year evaluation of available liver cell sources and cell culture formats being considered.

InSphero supplies assay-ready 3D microtissues and 3D-focused screening services to the pharmaceutical and cosmetics industry, counting the world's top 15 pharmaceutical companies as their clients.  InSphero's 3D InSight™ Human Liver Microtissues are established using PHH and other non-hepatocyte liver cells using a proprietary process and the company's hanging drop platform.  Growing the cells in 3D results in a long-lived microtissue that more accurately mimics the cell architecture and metabolic phenotype of native liver compared to traditional 2D cultured PHH.

For more information about InSphero, visit www.insphero.com.

InSphero contact

Dr. Randy Strube, Director of Global Marketing, phone +1 800-779-7558 ext. 102, This email address is being protected from spambots. You need JavaScript enabled to view it., www.insphero.com

Dr. Jan Lichtenberg, CEO and Co-Founder, phone +41 44 5150490, This email address is being protected from spambots. You need JavaScript enabled to view it.www.insphero.com

Disclaimer

MIP-DILI is jointly funded by EFPIA and Innovative Medicines Initiative. The press release by no means endorses MIP-DILI or its members in using InSphero products for drug discovery & development. MIP DILI endorses/recognizes the imperative value of comparing the quantitative evaluation of all test systems for drug safety evaluation in line with its primary objective http://www.mip-dili.eu/

About InSphero

InSphero is a leading supplier of organotypic, biological in vitro 3D microtissues for highly predictive drug testing. The company, headquartered in Zurich, Switzerland, with subsidiaries in the USA and in Germany, currently counts all of the top ten global pharmaceutical and cosmetics companies as customers. InSphero 3D Insight™ Microtissues enable more biologically relevant in vitro applications in efficacy and toxicology. The spin-off company of the Swiss Federal Institute of Technology (ETH) Zurich and the University Zurich has been recognized for its scientific and commercial achievements with a number of national and international awards, including being named the #1 Swiss Startup for 2014. InSphero is certified to the ISO 9001:2008 standard for its Quality Management System.

Follow us on twitternewsletter and www.insphero.com

 

Media Release images

For a high-resolution view click on an image below.

28.05.2014
Pancreatic Microislets for Diabetes

Media release 28.05.2014 - Pancreatic Microislets for Diabetes

11.04.2014
Dainippon Screen Cell3iMager

Media release 11.04.2014 - Dainippon Screen Cell3iMager

11.04.2014
96well Spheroids

Media release 11.04.2014 - 96well Spheroids

11.04.2014
Tumor Spheroid

Media release 20.03.2014 - Tumor Spheroid

 

20.03.2014
3D Tumor Microtissue

Tumor cells grown in 3D spheroids

27.02.2014
GravityPLUS plate

gravity-plus-culture-assay-96-plate

27.02.2014
3D InSight Tumor Microtissue

insphero-tumor-microtissue2

30.01.2014
Rat Liver

inspherp-rat-liver-thumb

28.01.2014
R. Strube

insphero-randy-strube-thumb

 

Media Releases Archive

Company video

company-video-inspheor

Contact us

Have a Question?

InSphero Locations

InSphero Distributors

Connect with us

icon-twittericon-linkedinicon-youtube

 InSphero Newsletter